Back to search

National and Kapodistrian University of Athens

The role of lysosome function in degradation of proteins that are associated with Parkinson's disease

Abstract

dc:description

Glucocerebrosidase gene (GBA1) mutations are the most common genetic contributor to Parkinson’s disease (PD). Moreover, mutations of GBA1 have been correlated with decreased activity of the lysosomic enzyme glucocerebrosidase (GCase) in PD patients, while PD patients not carrying a GBA1 mutation also exhibit low enzymatic activity of GCase in the central nervous system. In total, it seems that the activity of this specific enzyme is an important factor in PD pathogenesis. The most plausible mechanism through which GBA1 mutations contribute to the risk of developing PD is an alteration of the lysosome pathway of protein degradation. α-Synuclein, a protein with a central role in PD pathogenesis, has been shown to be secreted extracellularly, both as a free form protein and in association with exosomes. A dysregulation of the endocytic pathway through the dysfunction of GCase could result in an alteration of exosome and exosome-associated α-synuclein secretion.The aim of this study was to examine whether manipulating GCase activity and form both in vivo and in vitro could affect α-synuclein accumulation and secretion.In the first part of this dissertation, four adenoviruses were constructed containing four different genes respectively; wild type (WT) GBA, mutant N370S GBA, mutant D409V GBA and a gene encoding for green fluorescent protein (GFP) as a positive control. The viruses were used to transduce primary cortical neuronal cultures acquired by embryonic mice dissection. The adenovirus-mediated overexpression of WT GCase resulted in a significant decrease of exosome secretion in vitro. Intracellular and extracellular α-Synuclein levels showed a trend of increase that was not statistically significant.In the second part of the dissertation, in new in vitro experiments, the contribution of the activity of GCase to α-synuclein levels was investigated by adding conduritol-B epoxide (CBE), a selective inhibitor of GCase, in the presence of adenovirus-mediated α-synuclein overexpression. A non-significant trend of increase of α-synuclein levels was observed in the presence of CBE inhibition.In the third part of the dissertation, in vivo experiments were performed. Transgenic mice heterozygous for the A53T mutation of the gene encoding for α-synuclein (SNCA) were chosen. In this PD model, a chronic inhibition of the GCase enzyme was achieved by intraperitoneal injections of CBE in specific time intervals. The scheme adopted allowed us to emulate the chronic enzymatic activity decrease of GCase in PD patients. The intracellular oligomeric form of α-synuclein was significantly increased in the mice that received the CBE inhibitor. More specifically, GCase inhibition resulted in profound increase of brain exosomes and oligomeric α-synuclein contained in exosomes. Followingly, in order to examine the role of mutant GCase in a chronic model of PD, adeno-associated viruses were used to overexpress mutant GCase in the striatum of A53T SNCA transgenic mice. Using microdialysis, we were able to measure secreted α-synuclein levels in the same region. Interestingly, mice overexpressing N370S mutant GCase showed an increased secretion of α-synuclein. In further experiments, it was revealed that the α-synuclein secretion increase was due to lysosomal impairment, as observed by immunohistochemical staining for the LC3 autophagy marker.In conclusion, this dissertation resulted in interesting, novel findings. Our results suggest that, in a chronic in vivo model of PD, GCase activity decrease or mutant GCase overexpression result in α-synuclein secretion increase. It seems that this alteration is, at least in part, due to an autophagy impairment. This GCase effect could lead to increased α-synuclein secretion, driving pathology in GBA-associated PD. Exosome-associated oligomeric α-synuclein, apart from a therapeutic target, may also prove to be a relevant biomarker for PD, and thus the study of its modifiers, such as GCase shown here, may prove to be clinically relevant.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2018

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Papadopoulos, Vasileios
  • Παπαδόπουλος, Βασίλειος

Subjects

dc:subject × 23

Rights

Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/44377

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Papadopoulos, Vasileios; Παπαδόπουλος, Βασίλειος. The role of lysosome function in degradation of proteins that are associated with Parkinson's disease. National and Kapodistrian University of Athens, 2018. http://hdl.handle.net/10442/hedi/44377